search
Back to results

Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma

Primary Purpose

Carcinoma, Pancreatic Ductal

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Extended lymphadenectomy
Standard lymphadenectomy
Sponsored by
West China Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carcinoma, Pancreatic Ductal

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subject was diagnosed with pancreatic ductal adenocarcinoma supported by pathological and radiological examination preoperatively
  • Subject with absence of vascular invasion and metastasis
  • Subject with absence of prior history of cancer

Exclusion Criteria:

  • Subject was diagnosed that other pancreatic tumour types (neuroendocrine tumors, intraductal papillary mucinous neoplasm, serous cystadenoma, mucinous cystadenocarcinoma, solid pseudopapillary neoplasm and pancreatitis)
  • Subject was found with liver, omental, mesenteric or peritoneal metastasis intraoperatively
  • Subject with presence of other significant diseases (e.g., coronary heart disease)

Sites / Locations

  • West China HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Extended lymphadenectomy

Standard lymphadenectomy

Arm Description

In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.

Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.

Outcomes

Primary Outcome Measures

5-year overall survival rate
The percentage of patients that are alive at a 5 year

Secondary Outcome Measures

Postoperative pancreatic fistula
ISGPS definition
Bile leakage
ISGLS definition
Delayed gastric emptying
ISGPS definition
Post-pancreatectomy haemorrhage
ISGPS definition
Intra-abdominal infection
Presence of fever, signs of peritonitis, high leukocytes count or positive peritoneal drainage fluid culture
Wound infection
Requiring invasive treatment, for example: positive wound exudate culture and requiring continuous re-open drainage or invasive treatment
Postoperative mortality
Death due to any cause before or at postoperative day 30 and 60
Quality of life
EORTC QLQ-C30, according to the scoring manual published by the EORTC Quality of Life group
5-year disease-free survival rate
The percentage of patients alive without recurrence at a 5 year

Full Information

First Posted
October 6, 2016
Last Updated
October 6, 2016
Sponsor
West China Hospital
Collaborators
Royal Liverpool University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02928081
Brief Title
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
Official Title
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2016 (undefined)
Primary Completion Date
February 2021 (Anticipated)
Study Completion Date
April 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
West China Hospital
Collaborators
Royal Liverpool University Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of this study is to determine whether the performance of extended lymphadenectomy in association with pancreatoduodenectomy improves the long-term survival in patients with pancreatic head ductal adenocarcinoma.Half of participants will receive pancreatoduodenectomy with extended lymphadenectomy,while the other half will receive pancreatoduodenectomy with standard lymphadenectomy.
Detailed Description
Pancreatic cancer is a common malignant disease of the digestive system, and its incidence has been steadily increasing recently. Currently, the only potential curative treatment for pancreatic cancer is radical surgery. However, due to the peculiarity of the anatomical location of pancreas (in the retroperitoneum, surrounded by peripheral nerves and blood vessels) and its biological characteristics (neurotropic, highly malignant, and with probable skip metastasis), it is difficult to achieve R0 resection in patients with pancreatic cancer. High postoperative recurrence and distant metastasis rate are key factors in reducing long-term survival of patients with pancreatic cancer. The radical surgery modalities for pancreatoduodenectomy to achieve R0 resection involve extended lymphadenectomy, multivisceral resections, with or without simultaneous vein removals. Currently, the lymphadenectomy extent and approaches used to achieve R0 status are diverse. In 2014, the International Study Group for Pancreatic Surgery (ISGPS) reached a consensus to strive to resect lymph nodes (LNs) 5, 6, 8a, 12b1, 12b2, 12c, 13a, 13b, 14a, 14b, 17a, and 17b in standard lymphadenectomy for pancreatoduodenectomy. However, no consensus was reached on dissection of LN 16 due to variation in the literature and different expert opinions. On the current evidence, benefit of extended lymph node dissection seems to be outweighed by the risks. But deficiencies exist in the design of previous RCTs, such as insufficient sample size, lack of certain critical data for statistical analysis, inclusion of other pathological types of pancreatic neoplasms and variable retroperitoneal lymph node resection and nerve plexus dissection . Therefore, the power of evidence was low. Most studies report a high frequency of lymph node metastasis to LNs 13, 14, 17, 12 and 16 in pancreatic cancer, and tendency to metastasis from LNs 13, 14 to LN 16. In a lot of case reports, only nodal station 16a2 and 16b1 were positive in LN 16. This study is performed to confirm whether pancreatoduodenectomy with extended lymphadenectomy could improve survival. Subjects undergoing surgery will be randomized to pancreatoduodenectomy with extended lymphadenectomy including nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) versus standard pancreatoduodenectomy. Subjects will be followed every three months for survivorship or death. The primary endpoint of 5-year overall or disease-free survival survival will be determined at five year post surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carcinoma, Pancreatic Ductal

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
320 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Extended lymphadenectomy
Arm Type
Experimental
Arm Description
In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.
Arm Title
Standard lymphadenectomy
Arm Type
Other
Arm Description
Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.
Intervention Type
Procedure
Intervention Name(s)
Extended lymphadenectomy
Intervention Description
Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
Intervention Type
Procedure
Intervention Name(s)
Standard lymphadenectomy
Intervention Description
Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
Primary Outcome Measure Information:
Title
5-year overall survival rate
Description
The percentage of patients that are alive at a 5 year
Time Frame
5 years
Secondary Outcome Measure Information:
Title
Postoperative pancreatic fistula
Description
ISGPS definition
Time Frame
Within 30 days or before discharge
Title
Bile leakage
Description
ISGLS definition
Time Frame
Within 30 days or before discharge
Title
Delayed gastric emptying
Description
ISGPS definition
Time Frame
Within 30 days or before discharge
Title
Post-pancreatectomy haemorrhage
Description
ISGPS definition
Time Frame
Within 30 days or before discharge
Title
Intra-abdominal infection
Description
Presence of fever, signs of peritonitis, high leukocytes count or positive peritoneal drainage fluid culture
Time Frame
Within 30 days or before discharge
Title
Wound infection
Description
Requiring invasive treatment, for example: positive wound exudate culture and requiring continuous re-open drainage or invasive treatment
Time Frame
Within 30 days or before discharge
Title
Postoperative mortality
Description
Death due to any cause before or at postoperative day 30 and 60
Time Frame
Within 30 days or 60 days
Title
Quality of life
Description
EORTC QLQ-C30, according to the scoring manual published by the EORTC Quality of Life group
Time Frame
1 or 3 or 5 year
Title
5-year disease-free survival rate
Description
The percentage of patients alive without recurrence at a 5 year
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subject was diagnosed with pancreatic ductal adenocarcinoma supported by pathological and radiological examination preoperatively Subject with absence of vascular invasion and metastasis Subject with absence of prior history of cancer Exclusion Criteria: Subject was diagnosed that other pancreatic tumour types (neuroendocrine tumors, intraductal papillary mucinous neoplasm, serous cystadenoma, mucinous cystadenocarcinoma, solid pseudopapillary neoplasm and pancreatitis) Subject was found with liver, omental, mesenteric or peritoneal metastasis intraoperatively Subject with presence of other significant diseases (e.g., coronary heart disease)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xubao Liu, MD
Phone
86-28-85422474
Email
liuxb2011@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Junjie Xiong, MD
Phone
86-28-85422474
Email
junjiex2011@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hongyu Chen, MD
Organizational Affiliation
West China Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
West China Hospital
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xubao Liu, MD
Phone
86-28-85422474
Email
liuxb2011@126.com
First Name & Middle Initial & Last Name & Degree
Junjie Xiong, MD
Phone
86-28-85422474
Email
junjiex2011@126.com
First Name & Middle Initial & Last Name & Degree
Junjie Xiong, MD
First Name & Middle Initial & Last Name & Degree
Hongyu Chen, MD
First Name & Middle Initial & Last Name & Degree
Nengwen Ke, MD
First Name & Middle Initial & Last Name & Degree
Chunlu Tan, MD
First Name & Middle Initial & Last Name & Degree
Hao Zhang, MD
First Name & Middle Initial & Last Name & Degree
Ming Yang, MD
First Name & Middle Initial & Last Name & Degree
Bole Tian, MD
First Name & Middle Initial & Last Name & Degree
Weiming Hu, MD
First Name & Middle Initial & Last Name & Degree
Kezhou Li, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27149448
Citation
Xiong J, Szatmary P, Huang W, de la Iglesia-Garcia D, Nunes QM, Xia Q, Hu W, Sutton R, Liu X, Raraty MG. Enhanced Recovery After Surgery Program in Patients Undergoing Pancreaticoduodenectomy: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016 May;95(18):e3497. doi: 10.1097/MD.0000000000003497.
Results Reference
background
PubMed Identifier
25042895
Citation
Xiong JJ, Tan CL, Szatmary P, Huang W, Ke NW, Hu WM, Nunes QM, Sutton R, Liu XB. Meta-analysis of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Br J Surg. 2014 Sep;101(10):1196-208. doi: 10.1002/bjs.9553. Epub 2014 Jul 16.
Results Reference
background
PubMed Identifier
25175768
Citation
Chen Y, Ke N, Tan C, Zhang H, Wang X, Mai G, Liu X. Continuous versus interrupted suture techniques of pancreaticojejunostomy after pancreaticoduodenectomy. J Surg Res. 2015 Feb;193(2):590-7. doi: 10.1016/j.jss.2014.07.066. Epub 2014 Aug 5.
Results Reference
result
PubMed Identifier
24054418
Citation
Chen Y, Tan C, Mai G, Ke N, Liu X. Resection of pancreatic tumors involving the anterior surface of the superior mesenteric/portal veins axis: an alternative procedure to pancreaticoduodenectomy with vein resection. J Am Coll Surg. 2013 Oct;217(4):e21-8. doi: 10.1016/j.jamcollsurg.2013.07.383. No abstract available.
Results Reference
result
PubMed Identifier
25141915
Citation
Chen Y, Wang X, Ke N, Mai G, Liu X. Inferior mesenteric vein serves as an alternative guide for transection of the pancreatic body during pancreaticoduodenectomy with concomitant vascular resection: a comparative study evaluating perioperative outcomes. Eur J Med Res. 2014 Aug 21;19(1):42. doi: 10.1186/s40001-014-0042-z.
Results Reference
result
PubMed Identifier
22038501
Citation
Nimura Y, Nagino M, Takao S, Takada T, Miyazaki K, Kawarada Y, Miyagawa S, Yamaguchi A, Ishiyama S, Takeda Y, Sakoda K, Kinoshita T, Yasui K, Shimada H, Katoh H. Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci. 2012 May;19(3):230-41. doi: 10.1007/s00534-011-0466-6.
Results Reference
result
PubMed Identifier
24368638
Citation
Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ, Han SS, Yoon DS, Yu HC, Kang KJ, Kim SG, Kim SW. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 2014 Apr;259(4):656-64. doi: 10.1097/SLA.0000000000000384.
Results Reference
result
PubMed Identifier
34477122
Citation
Wang Z, Ke N, Wang X, Wang X, Chen Y, Chen H, Liu J, He D, Tian B, Li A, Hu W, Li K, Liu X. Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study. Medicine (Baltimore). 2021 Sep 3;100(35):e26918. doi: 10.1097/MD.0000000000026918.
Results Reference
derived

Learn more about this trial

Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma

We'll reach out to this number within 24 hrs